Physician profile
Gregory Laffoon
NPI 1831155910
$7,443.74
in general payments reported to CMS, 2019-2025
14 companies · $16.56 in 2025
The $16.56 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $47.95 · 2021: $58.89 · 2022: $67.59 · 2023: $6,958 · 2024: $186 · 2025: $16.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,500 · Travel and Lodging: $1,291 · Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,500.00 |
| Travel and Lodging | $1,290.65 |
| Food and Beverage | $370.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,997.62 | 2023-2024 | Davinci Xi, Da Vinci Surgical System |
| Smith+Nephew, INC. | $118.04 | 2019-2024 | Stravix |
| Davol INC. | $89.16 | 2024 | Arista Ah Flexitip, Tridyne Vascular Sealant |
| Innocoll Pharmaceuticals Limited | $39.21 | 2021-2022 | |
| Allergan, INC. | $36.74 | 2019 | |
| Livanova USA, INC. | $26.53 | 2019 | |
| Hydrofera LLC | $21.42 | 2024 | Hydrofera Blue |
| Integra Lifesciences Corporation | $18.29 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.13 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $16.56 | 2025 | Exparel |
| Z-Medica, LLC | $16.24 | 2020 | |
| Kci USA, INC. | $16.14 | 2021 | |
| Abbvie INC. | $16.08 | 2022 | |
| Biogen, INC. | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Laffoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.